Expert consensus decision pathway for anticoagulant and antiplatelet use in patients with atherosclerotic cardiovascular disease or in those with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention.
Researchers theorized that disparities between the sexes in the management of MI had changed over time, altering the prognoses after MI, especially the risk for heart failure.
A new-generation drug-coated balloon outperformed an evrolimus-eluting stent for the treatment of small vessel CAD lesions.
Lipid-lowering pharmacotherapy targeting LDL-C was found to be safe and effective in reducing CV and cerebrovascular events, with similar efficacy in older and younger patients.
Anticoagulants, antiplatelets, and thrombolytics for the treatment and/or prophylaxis of venous and arterial thrombosis.
Therapies which improve endothelial dysfunction should be considered for the treatment of patients with COVID-19-and acute coronary syndrome.
For patients with acute coronary syndrome (ACS), hostility predicts all-cause mortality but not recurrence.
Early initiation of rhythm control therapy was found to reduce cardiovascular outcomes in patients with early atrial fibrillation and cardiovascular conditions.
Adding multiproteomic biomarkers to a clinical risk model for the evaluation of patients with diabetes and a recent myocardial infarction may provide better risk assessment.
The incidence of stress cardiomyopathy has increased during the COVID-19 pandemic.
